Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Yumanity Therapeutics, Inc. (YMTX : NSDQ)
 
 • Company Description   
Yumanity Therapeutics Inc. is a clinical-stage biopharmaceutical company involved in the treatment of neurodegenerative diseases. The company's product candidate includes YTX-7739.Yumanity Therapeutics Inc., formerly known as Proteostasis Therapeutics Inc., is based in BOSTON.

Number of Employees: 41

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.11 Daily Weekly Monthly
20 Day Moving Average: 48,220 shares
Shares Outstanding: 10.84 (millions)
Market Capitalization: $12.04 (millions)
Beta: 0.88
52 Week High: $16.89
52 Week Low: $0.95
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -6.72% 2.13%
12 Week -14.61% -4.04%
Year To Date -62.50% -54.19%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
40 GUEST STREET SUITE 4410
-
BOSTON,MA 02135
USA
ph: 617-409-5300
fax: -
lroth@burnsmc.com http://www.yumanity.com
 
 • General Corporate Information   
Officers
Richard Peters - Chief Executive Officer and President
Michael D. Wyzga - Senior Vice President and Chief Financial Officer
Marie Epstein - Vice President
Patricia L. Allen - Director
David Arkowitz - Director

Peer Information
Yumanity Therapeutics, Inc. (CORR.)
Yumanity Therapeutics, Inc. (RSPI)
Yumanity Therapeutics, Inc. (CGXP)
Yumanity Therapeutics, Inc. (BGEN)
Yumanity Therapeutics, Inc. (GTBP)
Yumanity Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 98872L102
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/11/22
Share - Related Items
Shares Outstanding: 10.84
Most Recent Split Date: 12.00 (0.05:1)
Beta: 0.88
Market Capitalization: $12.04 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.06 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-4.42 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.03
Price/Cash Flow: -
Price / Sales: 2.17
EPS Growth
vs. Year Ago Period: -45.88%
vs. Previous Quarter: -24.00%
Sales Growth
vs. Year Ago Period: -71.04%
vs. Previous Quarter: 34.25%
ROE
03/31/22 - -162.54
12/31/21 - -108.22
09/30/21 - -147.18
ROA
03/31/22 - -72.00
12/31/21 - -51.59
09/30/21 - -73.43
Current Ratio
03/31/22 - 1.90
12/31/21 - 1.88
09/30/21 - 2.70
Quick Ratio
03/31/22 - 1.90
12/31/21 - 1.88
09/30/21 - 2.70
Operating Margin
03/31/22 - -798.73
12/31/21 - -491.15
09/30/21 - -605.00
Net Margin
03/31/22 - -798.73
12/31/21 - -491.15
09/30/21 - -605.00
Pre-Tax Margin
03/31/22 - -798.73
12/31/21 - -491.09
09/30/21 - -605.00
Book Value
03/31/22 - 1.08
12/31/21 - 2.28
09/30/21 - 3.15
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.31
09/30/21 - 0.27
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 23.84
09/30/21 - 21.23
 

Powered by Zacks Investment Research ©